Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women

2014158 citationsJournal Articlebronze Open Access

Authors

Erna M. Kojic · Brown University

Minhee Kang · Cancer Research And Biostatistics

Michelle Cespedes · Icahn School of Medicine at Mount Sinai

Triin Umbleja · Cancer Research And Biostatistics

Catherine Godfrey · National Institute of Allergy and Infectious Diseases

R. T. Allen · AIDS Clinical Trials Group

Cindy Firnhaber

Abstract

The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic in HIV-infected women aged 13-45 years. Women with HIV RNA load >10 000 copies/mL and/or CD4 count <200 cells/µL had lower rates of seroconversion rates. Clinical Trials Registration. NCT00604175.

Topics & Keywords

Cervical Cancer and HPV Research Hepatitis B Virus Studies Genital Health and Disease

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 59, Issue 1, pp. 127-135

DOI: 10.1093/cid/ciu238

Field-Weighted Citation Impact: 11.15